Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients
Improvements in the outcomes of patients with gMG, including patients with severe gMG, myasthenic crisis, and refractory to anti-complementary therapy, were observed after the first cycle of efgartigimod treatment. Our real-world experience in Japan suggests the future possibilities for the treatment with efgartigimod for gMG with diverse backgrounds.
Authors
- Michie Imamura
- Mitsuharu Ueda (ORCID: https://orcid.org/0000-0002-6814-0582)
- Toshiya Nomura (ORCID: https://orcid.org/0000-0001-9657-5324)
- Hirotake Mizutani (ORCID: https://orcid.org/0000-0003-3320-9655)
- Masao Imura
Institutions
- Kumamoto University (JP)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-10-14
- DOI
- https://doi.org/10.3389/fneur.2024.1472845
- Citations
- 10
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 3.69
Funders
- Argenx